The proprotein convertase furin plays a crucial role in a variety of pathogenic processes such as cancer, bacterial and viral diseases, neurodegenerative disorders and diabetes. Thus, furin inhibitors are promising therapeutics for the treatment of many diseases. In this study we synthesized some new non-peptide of furin inhibitors, with positively charged amidinohydrazone groups present in ortho-, meta-or para-positions in the benzene rings relative to the linker. From the results of biological testing it followed that the position of amidinohydrazone groups in aromatic rings was significant for the manifestation of antifurin activity. The replacement of linkers containing a propoxy group by a "bridge" with a benzene ring was found to cause an increase in the inhibitory effect of the compounds. The effect of synthesized bisamidinohydrazones on furin also depended on the substitution of the hydrogen atom in the amidinohydrazone group by the methyl group. These compounds were shown to block the enzyme activity mainly by the mechanism of mixed inhibition, and their k i values were at the micromolar level. k e y w o r d s: furin, amidinohydrazones, furin inhibitors, inhibition mechanism.
I t is well known that many intracellular proteins in eukaryotes are initially synthesized in the form of large inactive precursors (proproteins). They are then transformed into smaller mature biologically active products: hormones, neuropeptides, enzymes and proteins as a result of controlled cleava ge of the corresponding polypeptides by specialized enzymes known as proprotein convertases (PCs) [1] [2] [3] [4] [5] . The most characterized member of mammalian PCs is calcium-dependent serine endoprotease furin, which recognizes in its substrates a motif enriched with the residues of basic amino acids : -(Lys/Arg)-(Xxx)n-(Lys/Arg)-↓, where n = 0, 2, 4 or 6 and Xxx is any proteinogenic amino acid other than Cys [1, 3, 5] . Furin cleaves the peptide bond (indicated by the arrow) typically after a pair of basic amino acids Arg-Lys or Arg-Arg [1, 2] . This enzyme is important for embryogenesis and homeostasis; it also participates in many pathological processes, such as cancer and metastasizing, neurodegenerative patholo gies, viral and bacterial infections [3] [4] [5] [6] . In this regard, furin is considered as a promising and important target for developing of appropriate inhibitors, which could find clinical and therapeutic applications [3] [4] [5] [6] [7] . In works published in recent years, furin inhibitors of the protein, peptide, pseudopeptide and non-peptide nature have been discussed [7] [8] [9] [10] [11] [12] [13] [14] [15] . It was concluded that new research is needed to create non-peptidic low molecular weight inhibitors that, in comparison to the endogenous and recombinant proteins would have advantages such as increased stability, enhanced bioavailability and easier production by synthetic methods [7, 8] .
To develop the strategy for creating non-peptide inhibitors of furin, we drew attention to the article by Sielaff F. et al. [16] devoted to the synthesis and investigation of the properties of compounds containing an amidinohydrazone group. Encourages by this work, we synthesized previously nonpeptidic furin inhibitors with a general formula a (Fig. 1) containing two aryl rings joined by a linker X, differing in their chemical nature, length and hydrophobicity [17, 18] . Synthesis of similar bisamidinohydrazones as extremely active compounds with bactericidal activity were described in the US patent [19] . In work by Borges M. N. et al. [20] some analogs were synthesized and tested as anti-Trypanosoma cruzi candidate.
The aim of this work was the synthesis of new bisamidinohydrazones containing positively charged groups in the ortho-, meta-or para-positions with respect to the linker, and testing the resulting compounds as novel furin inhibitors.
materials and methods
Analytical grade chemicals and solvents were purchased from commercial suppliers and used without further purification. When necessary, solvents were dried by standard techniques and distilled. Melting points (uncorrected.) were determined using Fisher Scientific apparatus IR spectra were recor ded on a Bruker Vertex 70 FT/IR spectrometer.
1 Н NMR spectra were recorded in dimethyl sulfoxide (DMSO)-d 6 using 400 MHz Varian Mercury instrument with tetramethylsilane (TMS) as the internal standard. Chemical shifts (δ scale) were expressed in parts per million (ppm) and given as s (singlet), bs (broad singlet), d (doublet), t (triplet), m (multiplet) and q (quintet). Relative fluorescence was measured using spectrofluorometer PTI Quanta Master 40 (Canada) with excitation at 380 nm and emission at 460 nm. chemical reagents and preparations. A fluorogenic substrate t-butyl-oxycarbonyl-L-arginyl-L-valyl-L-arginyl-L-arginine-4-methylcoumaryl-7-amide (Boc-Arg-Val-Arg-Arg-AMC) was purchased from Bachem (Switzerland). The recombinant truncated human furin (2000 units/ml) was obtained from New England BioLabs (USA). The commercial stock enzyme solution was diluted 20-to 80-fold with a buffer (pH 7.3; 100 mM Hepes, 1 mM CaCl 2 , 0.5% Triton X-100 and 1 mM β-mercaptoethanol) and used in enzymatic reactions. One unit of furin activity was defined as the quantity of an enzyme that under standard conditions cleaved off 1 picamol of 7-amino-4-methylcoumarin (AMC) in 1 min.
bis(2-carboxyaldehydophenoxy)propane (2a).
A mixture of 2-hydroxybenzaldehyde (3.7 g, 30 mmol), 1,3-dibromopropane (1.5 ml, 15 mmol) and anhydrous potassium carbonate (8.3 g, 60 mmol) was refluxed in 30 ml anhydrous acetone for 18 h, and then the solvent was removed in a vacuum of a water jet pump. The residue was washed with distilled water (50 ml x 1) and extracted with chloroform (50 ml x 3). The combined organic layer was dried over Na 2 SO 4 and, after filtration, the solvent was removed in vacuum and the residue was crystallized from 95% ethanol. Similarly, other bisaldehydes (2b, c) and bisketones (2d-f) were obtained.
4-[4 (4-formylphenoxy)phenoxy]benzaldehyde (5b).
4.15 g (30 mmol) of anhydrous K 2 CO 3 was added to a solution of 11.0 g (10 mmol) of hydroquinone and 2.48 g (20 mmol) of 4-fluorobenzaldehyde in 20 ml of dimethylacetamide (DMAA). The mixture was heated for 12 h at a temperature 90 °C. DMAA was poured off from insoluble K 2 CO 3 , and after cooling the product was precipitated with distilled water, filtered and crystallized from the mixture of isopropyl alcohol-water. a general procedure for synthesis of bisamidinohydrazones. A mixture of 2 mmol of the corresponding dialdehyde (2a-c, 5a-b) or diketone (2d-f) and aminoguanidine hydrochloride (0.46 g, 4.1 mmol) was refluxed for 4 h in 20 ml of 95% ethanol containing several drops of concentrated HCl. After cooling the mixture to room temperature, the solvent was removed in vacuo and the residue was triturated with chloroform. The solidified mass was filtered off and purified by crystallization from a suitable solvent. Determination of the inhibitory effects of bisamidinohydrazones. To prepare a stock solution (concentration 10 mM), a sample of the corresponding compound was dissolved in DMSO. Then the stock solution was diluted to the required concentration. The enzyme solution (1 unit of activi ty), a pH 7.3 buffer and the studied inhibitor (concentration 5-10 μМ) were incubated at room temperature for 30 min. Then a solution of fluorogenic substrate was added to reach its final concentration of 100 μM and the enzymatic reaction was run for 1 h at 37 °C. The total volume of the mixture was 150 μl. The reaction was terminated by adding 2 ml of the EDTA solution and the quantity of the released AMC was assayed against the buffer solution as described above. Enzyme activity in the absence of the studied compounds was assumed to be 100%. Inhibition constants k i were determined from Dixon or Lineweaver-Burk plots. Data analysis and plotting were carried out using Origin Professional 9.0 software (OriginLab). At least two measurements were used for each point. The experimental error did not exceed 10% of the measured value.
results and discussion chemistry. Synthesis of the investigated bisamidinohydrazones was carried out according to Scheme 1 [17] [18] [19] [20] . The dialdehydes (2a-c) were easily formed by boiling hydroxybenzaldehydes (1a-c) with 1,3-dibromopropane in dry acetone in the presence of K 2 CO 3 with yields of about 60%. The reaction of hydroxyacetophenones (1d-f) under similar conditions gave bisacetophenones (2d-f) with practically the same yields ( Table 1 ). The reaction of 4-fluorobenzaldehyde with hydroquinone in dimethylacetamide for 12 h resulted in dialdehydes (5a-b) with a yield of about 70%. Bisamidinohydrazones (3a-f and 6a-b) were obtained by the reaction of bisaldehydes (2a-c, 5a-b) or bisketones (2d-f) with aminoguanidine hydrochloride in 95% ethanol. Their yields were, unfortunately, lower ( 
1-({[3-(4-{3-[(carbamimidamidoimino)methyl]phenoxy}phenoxy)phenyl]methylidene}ami-no) guanidine dihydrochloride (6a)
Reaction of 3-fluorobenzaldehyde and hydroquinone in DMAA at 90 °C gave bisaldehyde 5a (yield 55%, m.p. 153 °C), which was condensed with aminoguanidine hydrochloride as described in the Materials and Methods without further purification. This gave bisamidinohydrazone 6a as white solid; yeild 51%, m.p. 305 °C (dec.). According to preliminary data, this compound inhibits furin with k i = 1.07 ± 0.23 μM. 
Scheme 1. Synthesis of bisamidinohydrazones with 1,3-trimethylene linker (A) or hydroquinone linker (B

1-({[4-(4-{4-[(carbamimidamidoimino)methyl]phenoxy}phenoxy)phenyl]methylidene}ami-no) guanidine dihydrochloride (6b)
white solid; yeild 43%, m.p. 252-253 °C (dec.) This compound was synthesized in our work [18] .
Biology. Inhibitory analysis. Table 2 presents data on the antifurin activity of the synthesized bisamidinohydrazones. Analysis of these data indicated that the replacement of the linkers containing the propoxy group (compounds 3b, k i = 1.70 μM and 3c, k i = 2.69 μM), on the "bridges" with the phenyl ring (compounds 6a, k i = 1.07 μM and 6b, k i = 0.74 ± 0.08 μM), led to an increase in the inhibitory effect of the compounds. This conclusion coincides with the results of studies previously pub- [20, 26] lished by our group [17] and by other investigators of guanidilated aromatic compounds [27] . Among the derivatives (3a-c) with the amidinohydrazone group unsubstituted on the Megroup, the most active inhibitor was compound 3b (k i = 1.70 μM), which contains a positively charged group in the meta-position relative to the linker. The affinity to furin of ortho-and para-substituted bisamidinohydrazones 3a and 3c were reduced by approximately 1.6-fold in comparison with the meta-isomer 3b. In a series of Me-substituted derivatives (3d-f), the best inhibitor of the enzyme was the para-isomer 3f (k i = 1.43 μM).
From the biological activity testing it was evident that the position of amidinohydrazone groups in the aromatic rings was essential for the antifurin activity. The effect of synthesized bisamidinohydrazones on furin depended also on the chemical nature and hydrophobicity of the linker and on the substitution of the hydrogen atom for methyl in the amidino- 
Fig. 2. Competitive (A), non-competitive (B) and mixed (C) mechanisms of furin inhibition by different bisamidinohydrazones
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hydrazone group. These conclusions are supported by Sielaff F. et al. [16] and our previous publications [17, 18] .
According to our data, most of the synthesized bisamidinohydrazones inactivated furin by the mechanism of mixed inhibition. Exceptions were compounds 3a and 6a: the first was a non-competitive inhibitor, and the second was a competitive inactivator of furin (Fig. 2) . Until recently, only single examples of low-molecular non-competitive inhibitors of furin were known. Now it became clear that among bisamidinohydrazones there are many compounds that are mixed inhibitors of furin. Additional studies are needed to investigate the reasons for this phenomenon.
A series of novel non-peptide inhibitors of furin was designed and synthesized and their antifurin activities were evaluated. From the results of the in-hibitory screening it was evident that the position of the amidinohydrazone groups in the phenyl rings was essential for the antifurin activity.
The inhibitory effect of synthesized bisamidinohydrazones on the enzyme depended also on the chemical nature and hydrophobicity of the linker and on the substitution of the hydrogen atom for methyl in the amidinohydrazone group.
It was shown that compound 3a is a non-competitive inhibitor of furin, bisamidinohydrazone 6a inactivates furin by the mechanism of competitive inhibition, and the remaining compounds decrease the activity of the enzyme in a mixed inhibition type. Пропротеїнконвертаза фурин відіграє клю-чову роль у багатьох патологічних процесах, та-ких, наприклад, як рак, бактеріальні та вірусні захворювання, нейродегенеративні порушення та діабет. Тому інгібітори фурину можуть бути багатообіцяючими терапевтичними засобами для лікування цих захворювань. Нами було син-тезовано низку нових непептидних інгібіторів ензиму, які містили амідиногідразовані групи, що знаходилися в бензольних кільцях в орто-, мета-або пара-положеннях відносно лінкера. Із результатів біологічного тестування випливає, що положення амідиногідразонових груп в аро-матичних кільцях істотно впливало на анти-фуринову активність сполук. Знайдено, що заміна лінкерів, які містили пропокси-групу, на «місток» із бензольним кільцем, обумовлювала ріст інгібіторної активності цих сполук. Їх вплив на фурин залежав також від заміщення атома водню в амідиногідразоновому угрупованні на метильну групу. Показано, що ці сполу-ки блокують активність ензиму за механізмом змішаного інгібування, а значення k і синте-зованих бісамідиногідразонів знаходяться на мікромолярному рівні.
К л ю ч о в і с л о ва: фурин, амідино-гідразони, інгібітори фурину, механізм інгібування. Пропротеинконвертаза фурин играет ключевую роль в развитии многих патологи-ческих процессов, таких, например, как рак, бактериаль ные и вирусные инфекции, нейро-дегенеративные нарушения и диабет. В связи с этим ингибиторы фурина могут оказаться мно-гообещающими терапевтическими средствами для лечения этих заболеваний. Нами синтезиро-вано ряд новых непептидных ингибиторов фу-рина, содержащих амидиногидразоновые груп-пы, находящиеся в бензольных кольцах в орто-, мета-или пара-положениях относительно лин-кера. Из данных биологического тестирования следует, что положение амидиногидразоновых групп в ароматических кольцах существенно влияло на антифуриновую активность. Найде-но, что замена линкеров, содержащих пропокси-группу, на «мостик» с бензольным кольцом по-вышала ингибиторную активность соединений. Их влияние на фурин зависило также от заме-щения атома водорода в амидиногидразоновой группировке на метильную группу. Показано, что эти соединения блокируют активность энзи-ма по механизму смешанного ингибирования, а значения k i исследованных бисамидиногидразо-нов находятся на микромолярном уровне. К л ю ч е в ы е с л о в а: фурин, амидиноги-дразоны, ингибиторы фурина, механизм инги-бирования.
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